All News

Found 809 articles

• Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival

  4/18/2023

  Immunocore Holdings plc has presented four posters with KIMMTRAK data in HLA-A*02:01 patients with metastatic uveal melanoma, at the 2023 American Association for Cancer Research Annual Meeting 2023.

• GC Genome to Present the Brand New Liquid Biopsy Platform for Cancer Detection at AACR Annual Meeting 2023

  4/18/2023

  GC Genome Corporation, a leading diagnostics company, announced that the company will present data showcasing the deep learning algorithm that detects and classifies multi-cancer using methylation information and genomic data at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.

• DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

  4/16/2023

  DiaCarta, Ltd., a precision molecular diagnostics company, announced that it will present five data posters at the American Association of Cancer Research Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.

• QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023

  4/14/2023

  QIAGEN announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer and other diseases to turn cell-free DNA liquid-biopsy samples into libraries ready for next-generation sequencing in less than eight hours.

• BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW

  4/13/2023

  biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single low volume sample.

• Telo Genomics Achieves a Major Milestone - Results of Smoldering Myeloma Study Accepted for Presentation at ASCO Annual Meeting

  4/13/2023

  elo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) 2023 annual meeting was accepted for presentation and will be published in the official proceedings of the meeting.

• Menarini Silicon Biosystems new CELLSEARCH® data presented at AACR 2023 annual meeting highlights trailblazing contributions of liquid biopsies for cancer research

  4/13/2023

  Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today the data from two posters to be presented at the April 14-19, 2023 annual meeting of the American Association for Cancer Research (AACR).

• Alamar Biosciences Unveils Novel Proteomics Platform with Best-in-Class Sensitivity and High Multiplexing Capability

  4/12/2023

  Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced the unveiling of its technology platform NULISA™, a novel automated ultrasensitive and highly multiplexed proteomics technology for liquid biopsy.

• GRAIL Showcases Methylation Platform Performance Across Cancer Continuum With New Data at American Association for Cancer Research (AACR) Annual Meeting

  4/11/2023

  GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data showcasing the performance of its methylation platform to detect cancer across the early- and post-diagnosis settings at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14-19, 2023.

• Mercy BioAnalytics Raises $41 Million in Series A Financing to Advance Novel Mercy Halo Liquid Biopsy Platform for Early Cancer Detection

  4/3/2023

  Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, announced it has closed a $41 million Series A financing round.

• Stilla Technologies and Atila BioSystems to Co-Develop High-Plex Digital PCR Kits for Oncology

  3/30/2023

  Stilla Technologies and Atila BioSystems announced an agreement to market digital PCR kits and assays produced by Atila BioSystems for use on the naica® system.

• Mercy BioAnalytics Adds Scientific, Quality, and Regulatory Leadership in Preparation for Clinical Development

  3/23/2023

  Mercy BioAnalytics, Inc. today announced that it has added two senior executives as the Company transitions from research to clinical development. Toumy Guettouche, PhD has joined Mercy as the Chief Scientific Officer, and Michael Smith has joined as the company’s first Vice President for Quality, Regulatory, and Clinical Affairs.

• Droplet Biosciences Announces Lymph Diagnostic Platform to Help Prevent Cancer Recurrence

  3/16/2023

  Droplet Biosciences today announced an $8 million seed investment to establish proof of concept for the company’s technology.

• Telo Genomics Advances to Final Stage of Achieving ISO Certification

  3/15/2023

   Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that it has recently completed the interim assessment of its systems and protocols for ISO 15189 certification with over 90% compliance.

• BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting

  3/15/2023

  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 - 19, 2023 at Orange County Convention Center, Orlando, Florida.

• Immunocore to present four posters at AACR Annual Meeting 2023

  3/14/2023

  Immunocore Holdings plc will present four posters at the American Association for Cancer Research Annual Meeting 2023 commencing on 14 April 2023.

• Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results

  2/16/2023

  Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced financial results for the fourth quarter and full year ended December 31, 2022.

• Mercy BioAnalytics Announces Executive Leadership Changes

  2/15/2023

  Mercy BioAnalytics, Inc. announced that Dawn Mattoon, PhD, has assumed the role of Chief Executive Officer and a member of the company’s Board of Directors, transitioning from her prior role as Chief Operating Officer as part of the company’s succession planning.

• bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

  1/24/2023

  bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing results of the Company’s clinical trial for its non-invasive diagnostic CyPath ® Lung in Respiratory Research, one of the leading peer-reviewed open access journals in the field of respiratory medicine.

• Biological Dynamics to deliver showcase presentation at Precision Medicine World Conference

  1/24/2023

  Biological Dynamics’ Medical Director, Harmeet Dhani, MD, MSc to present data demonstrating clinical utility of the ExoVerita™ exosome-isolation platform for detection of early-stage cancers.